Involvement of Akt and mTOR in chemotherapeutic and hormonal-based drug resistance and response to radiation in breast cancer cells

Cell Cycle

Volumn 10, Issue 17, 2011, Pages 3003-3015

  Steelman, Linda S ^a   Navolanic, Patrick ^a   Chappell, William H ^a   Abrams, Stephen L ^a   Wong, Ellis W T ^a   Martelli, Alberto M ^b,c   Cocco, Lucio ^b   Stivala, Franca ^d   Libra, Massimo ^d   Nicoletti, Ferdinando ^d   Drobot, Lyudmyla B ^e   Franklin, Richard A ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e PALLADIN INSTITUTE OF BIOCHEMISTRY   (Ukraine)

Author keywords

Akt; Chemotherapeutic drugs; ERK; mTOR; Radiation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; GENE ACTIVATION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 80052398902     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.17.17119     Document Type: Article

References (110)

1. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 2005; 9:1009-30; PMID:16185155; DOI:10.1517/14728222. 9.5.1009.
2. Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009; 8:18-22; PMID:19106609; DOI:10.4161/cc.8.1.7324.
3. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909-15; PMID:19221498; DOI:10.4161/cc.8.6.7933.
4. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188-97; PMID:20016287; DOI:10.4161/cc.9.1.10407.
5. McCubrey JA, Steelman LS, Kempf CR, Chappell W, Abrams SL, Stivala F, et al. Therapeutic Resistance Resulting from Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways. J Cell Physiol 2011; In press.; DOI:10.1002/jcp.22647; PMID:21302297.
6. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001; 7:2898-907; PMID:11555608.
7. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003; 9:1161-70; PMID:12631622.
8. Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004; 8:537-50; PMID:15584861; DOI:10.1517/14728222.8.6.537.
9. Luo J, Cantley LC. The negative regulation of phosphoinositide-3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 2005; 4:1309-12; PMID:16131837; DOI:10.4161/cc.4.10.2062.
10. Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011; 3:192-222; PMID:21422497.
11. Chappell WH, Steelman LS, Long JM, Kempf CR, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rational and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64; PMID:21411864.
12. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors. Cell Cycle 2009; 8:1352-8; PMID:19305151; DOI:10.4161/cc.8.9.8255.
13. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol-3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89-103; PMID:20671809.
14. Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol- 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010; 9:596-600; PMID:20009532; DOI:10.4161/cc.9.3.10599.
15. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, et al. The emerging role of the phosphatiylinositol-3-kinase/Akt/ mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogensis. Biochem Biophys Act 2010; 1803:991-1002.
16. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997; 275:665-8; PMID:9005852; DOI:10.1126/science.275.5300.665.
17. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996; 271:31372-8; PMID:8940145; DOI:10.1074/jbc.271.49.31372.
18. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, et al. The emerging role of the phosphatiylinositol-3-kinase/Akt/ mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogensis. Biochim Biophys Act 2010; 1803:991-1002.
19. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7:261-9; PMID:9094314; DOI:10.1016/S0960-9822(06)00122-9.
20. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997; 277:567-70; PMID:9228007; DOI:10.1126/science. 277.5325.567.
21. Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009; 8:2502-8; PMID:19597332; DOI:10.4161/cc.8.16.9335.
22. Narasimhan SD, Mukhopadhyay A, Tissenbaum HA. InAKTivation of insulin/IGF-1 signaling by dephosphorylation. Cell Cycle 2009; 8:3878-84; PMID:19901535; DOI:10.4161/cc.8.23.10072.
23. Brauer PM, Tyner AL. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle 2009; 8:2728-32; PMID:19652529; DOI:10.4161/cc.8.17.9389.
24. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasiprogram. Cell Cycle 2010; 9:3151-6; PMID:20724817; DOI:10.4161/cc.9.16.13120.
25. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7:1020-35; PMID:18414053; DOI:10.4161/cc.7.8.5740.
26. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009; 8:1901-4; PMID:19471118; DOI:10.4161/cc.8.12.8810.
27. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900; PMID:19478560; DOI:10.4161/cc.8.12. 8809.
28. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95; PMID:19471117; DOI:10.4161/cc.8.12.8606.
29. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic decleration. Cell Cycle 2009; 8:1883-7; PMID:19448395; DOI:10.4161/cc.8.12.8815.
30. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010; 9:486-97; PMID:20081374; DOI:10.4161/cc.9.3. 10508.
31. Lal MA, Bae D, Camilli TC, Patierno SR, Ceryak S. AKT1 mediates bypass of the G1/S checkpoint after genotoxic stress in normal human cells. Cell Cycle 2009; 8:1589-602; PMID:19377290; DOI:10.4161/cc.8.10.8547.
32. Jin J, Wang GL, Timchenko L, Timchenko NA. GSK3beta and aging liver. Aging 2009; 1:582-5; PMID:20157540.
33. Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 2009; 8:1003-6; PMID:19270523; DOI:10.4161/cc.8.7.8045.
34. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010; 2:344-52; PMID:20606252.
35. Leslie NR, Foti M. Not in my genes: non-genomic loss of PTEN function in cancer. Trends Pharmacol Sci 2011; 32:131-40; PMID:21236500; DOI:10.1016/j.tips.2010.12.005.
36. Sayed D. Abdellatif M. AKT-ing via microRNA. Cell Cycle 2010; 9:3213-7; PMID:20814244; DOI:10.4161/cc.9.16.12634.
37. Singh B, Ittmann MM, Krolewski JJ. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 1998; 21:166-71; PMID:9491329; DOI:10.1002/(SICI)1098- 2264(199802)21:2〈166::AID-GCC13〉3.0.CO;2-P.
38. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005; 68:398-404; PMID:16020969; DOI:10.1159/000086981.
39. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7:965-70; PMID:18414037; DOI:10.4161/cc.7.8.5753.
40. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009; 8:2198-210; PMID:19502790; DOI:10.4161/cc.8.14.8947.
41. Diaz-Meco MT, Abu-Baker S. The Par-4/PTEN connection in tumor suppression. Cell Cycle 2009; 8:2518-22; PMID:19625770; DOI:10.4161/cc.8.16. 9384.
42. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009; 8:731-5; PMID:19221485; DOI:10.4161/cc.8.5.7848.
43. Poon JS, Eves R, Mak AS. Both lipid- and proteinphosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 2010; 9:4450-4; PMID:21084866; DOI:10.4161/cc.9.22.13936.
44. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; In press; PMID:21436840; DOI:10.1038/leu.2011.46.
45. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, et al. Roles of the Ras/Raf/MEK/ERK Pathway in Leukemia Therapy. Leukemia 2011; In press; PMID:21494257; DOI:10.1038/leu.2011.66.
46. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002; 33:405-9; PMID:12055674; DOI:10.1053/hupa.2002.124721.
47. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-17; PMID:12479367.
48. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13:137-44; PMID:16755107; DOI:10.2325/jbcs.13.137.
49. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10:8059-67; PMID:15585641; DOI:10.1158/1078-0432.CCR-04-0035.
50. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27; PMID:15324695; DOI:10.1016/j.ccr.2004.06.022.
51. Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 2005; 93:1372-81; PMID:16288304; DOI:10.1038/sj.bjc.6602862.
52. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66:2028-37; PMID:16489002; DOI:10.1158/0008-5472.CAN-04-4559.
53. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, Sinclair DA. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging 2009; 1:515-28; PMID:20157535.
54. Faridi J, Wang L, Endemann G, Roth RA. Expression of Constitutively Active Akt-3 in MCF-7 Breast Cancer Cells Reverses the Estrogen and Tamoxifen Responsivity of these Cells in Vivo. Clin Cancer Res 2003; 9:2933-9; PMID:12912939.
55. Steelman LS, Navolanic PN, Sokolosky M, Taylor JR, Lehmann BD, Chappell WH, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 2008; 27:4086-95; PMID:18332865; DOI:10.1038/onc.2008.49.
56. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong ET, Basecke J, et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008; 22:2080-90; PMID:18685611; DOI:10.1038/leu.2008.207.
57. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9:1781-91; PMID:20436278; DOI:10.4161/cc.9.9.11483.
58. Abrams SL, Steelman LS, Shelton JG, Chappell W, Basecke J, Stivala F, et al. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 2010; 9:1839-46; PMID:20436269; DOI:10.4161/cc.9.9.11544.
59. Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, et al. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010; 9:1629-38; PMID:20372086; DOI:10.4161/cc.9.8.11487.
60. + cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27:1749-58; PMID:17891174; DOI:10.1038/sj.onc.1210811.
61. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. PLoS Biol 2009; 7:1000121; PMID:19492080; DOI:10.1371/journal.pbio. 1000121.
62. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, et al. Targeting the leukemic stem cell-the holy grail of leukemia therapy. Leukemia 2009; 23:25-42; PMID:18800146; DOI:10.1038/leu.2008.246.
63. Buitenhuis M, Coffer PJ. The role of the PI3KPKB signaling module in regulation of hematopoiesis. Cell Cycle 2009; 8:560-6; PMID:19197152; DOI:10.4161/cc.8.4.7654.
64. Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, et al. Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle 2009; 8:3893-9; PMID:19934662; DOI:10.4161/cc.8.23.10091.
65. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403-13; PMID:19177005; DOI:10.4161/cc.8.3.7555.
66. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8:3831-7; PMID:19901542; DOI:10.4161/cc.8.23.10070.
67. Sabisz M, Skladonowski A. Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle 2009; 8:3208-17; PMID:19738435; DOI:10.4161/cc.8.19.9758.
68. McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, et al. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul 2010; 50:285-307; PMID:19895837; DOI:10.1016/j.advenzreg.2009.10.016.
69. McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, et al. Targeting the cancer initiating cells: the Achilles' heel of cancer. Adv Enzyme Regul 2011; 51:152-62; PMID:21035484; DOI:10.1016/j.advenzreg.2010.09. 002.
70. Mirza AM, Kohn AD, Roth RA, McMahon M. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ 2000; 11:279-92; PMID:10910095.
71. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003; 22:2478-92; PMID:12717425; DOI:10.1038/sj.onc.1206321.
72. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-4; PMID:10576742; DOI:10.1126/science.286.5445.1741.
73. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277:31099-106; PMID:12048182; DOI:10.1074/jbc.M111974200.
74. Migliaccio A, Pagano M, Auricchio F. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 1993; 8:2183-91; PMID:7687761.
75. Singh M, Sétáló G Jr, Guan X, Warren M, Toran-Allerand CD. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 1999; 19:1179-88; PMID:9952396.
76. Singh M, Sétáló G Jr, Guan X, Frail DE, Toran-Allerand CD. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J Neurosci 2000; 20:1694-700; PMID:10684871.
77. Ashcroft M, Kubbutat MHG, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19:1751-8; PMID:10022862.
78. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992; 12:5041-9; PMID:1406679.
79. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damageinduced phosphorylation of p53 alleviates inhibition by mdm2. Cell 1997; 91:325-34; PMID:9363941; DOI:10.1016/S0092-8674(00)80416-X.
80. Maclaine NJ, Hupp TR. The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging 2009; 1:490-502; PMID:20157532.
81. Huang B, Vassilev LT. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3. Aging 2009; 1:845-54; PMID:20157557.
82. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16 and SSRP1. Mol Cell 2001; 7:283-92; PMID:11239457; DOI:10.1016/S1097-2765(01)00176-9.
83. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007; 67:10466-74; PMID:17974990; DOI:10.1158/0008-5472.CAN-07-2090.
84. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53 and p21(CIP1), but not p16(INK4a). Mol Cell 2004; 14:501-13; PMID:15149599; DOI:10.1016/S1097-2765(04)00256-4.
85. Korotchkina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. Cellular quiescence caused by the Mdm-2 inhibitor nutlin-3A. Cell Cycle 2009; 8:3777-81; PMID:19855165; DOI:10.4161/cc.8.22.10121.
86. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660-4; PMID:20457898; DOI:10.1073/pnas.1002298107.
87. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2010; 2:924-35; PMID:21212465.
88. Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF, Rizos H. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging 2009; 1:542-56; PMID:20157537.
89. Vigneron A, Vousden KH. p53, ROS and senescence in the control of aging. Aging 2010; 2:471-4; PMID:20729567.
90. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2010; 2:924-35; PMID:21212465.
91. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007; 6:595-605; PMID:17351335; DOI:10.4161/cc.6.5.3901.
92. Labi V, Villunger A. PUMA-mediated tumor suppression: A tale of two stories. Cell Cycle 2010; 9:4269-75; PMID:20980816; DOI:10.4161/cc.9.21.13666.
93. Hill R, Lee PW. The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? Cell Cycle 2010; 9:3460-9; PMID:20855954; DOI:10.4161/cc.9.17.13043.
94. Kim DH, Rho K, Kim S. A theoretical model for p53 dynamics: identifying optimal therapeutic strategy for its activation and stabilization. Cell Cycle 2009; 8:3707-16; PMID:19844169; DOI:10.4161/cc.8.22.10023
95. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierre A, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8:1196-205; PMID:19305158; DOI:10.4161/cc.8.8.8203.
96. Dregalla RC, Zhou J, Idate RR, Battaglia CL, Liber HL, Bailey SM. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging 2010; 2:691-708; PMID:21037379.
97. Anisimov VN. Metformin for aging and cancer prevention. Aging 2010; 2:760-74; PMID:21084729.
98. Richardson RB. Ionizing radiation and aging: rejuvenating an old idea. Aging 2009; 1:887-902; PMID:20157573.
99. Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhu XF, et al. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 2011; 30:944-55; PMID:20956948; DOI:10.1038/onc.2010.467.
100. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009; 69:4252-9; PMID:19435898; DOI:10.1158/0008-5472.CAN-08-4853.
101. Xia S, Zhao Y, Yu S, Zhang M. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm 2010; 25:317-23; PMID:20578837; DOI:10.1089/cbr.2009.0707.
102. Krasny L. Shimony N, Tzukert K, Gorodetsky R, Lecht S, Nettelbeck DM, et al. An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells. Nephrol Dial Transplant 2010; 25:373-80; PMID:19828461; DOI:10.1093/ndt/gfp525.
103. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2009; 4:761-7; PMID:19404218.
104. Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, Kim BG, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006; 94:1678-82; PMID:16721365.
105. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2011; In press.
106. Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1; p53-deficient mammary tumor cells in vivo. Cell Cycle 2010; 9:3780-91; PMID:20855963; DOI:10.4161/cc.9.18.13002.
107. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010; 1:387-95; PMID:21311095.
108. Vicente-Dueñas C, Abollo-Jiménez F, Ruiz-Roca L, Alonso-Escudero E, Jiménez R, Cenador MB, et al. The age of the target cell affects B-cell leukaemia malignancy. Aging 2010; 2:908-13; PMID:21164221.
109. Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget 2010; 1:156-60; PMID:21297225.
110. Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, et al. Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle 2010; 9:1194-206; PMID:20237414; DOI:10.4161/cc.9.6.11108.